Ambalal Sarabhai Enterprises Ltd.
Snapshot View

31.00 +1.45 ▲4.9%

30 July 2021, 04:00:00 P.M.
Volume: 235,856

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ase.life
Financial Indicators
Market Cap 237.56 Cr.
Earnings per share (EPS) 3.83 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 8.09 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 8.48 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.65 Calculated using Price: 31.00
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 7.66 Cr. 76,633,296 Shares
FaceValue 10
Company Profile

Ambalal Sarabhai Enterprises is a Baroda-based pharmaceutical manufacturing company which was incorporated in 1977. It is one of the company belonging to the Sarabhai Group. The Group's principal activity is manufacture and marketing of pharmaceutical products and bulk drugs. The company's plants are located at Vadodara and Ahmedabad.

History of the company:-

1977: The company was incorporated on June 27, as a private limited company.  It was converted into a public limited company on December 29, 1980. The objects are manufacture of drugs and pharmaceuticals, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials. The company also carries on industrial research and consultancy services.

  • The restructuring and reorganization of various Sarabhai Enterprises:

(a) Elscope Private (Elscope) became the owner of the undertaking and business of Sarabhai Chemicals, Sarabhai Machinery and Bakubhai Ambalal; and

(b) Ofisade Private Limited (Ofisade) became the owner of undertakings and business of Sarabhai M Chemicals, Swastik Household and Industrial Products, Systronics, Telerad, ORG Systems and Operations Research Group, Packart, Cotton & Cloth and WIPS, Sarabhai Research Centre and Sarabhai Electronics Research Centre.

As a part of the reorganization, the company also acquired from Shahibag Entrepreneurs Pvt. Ltd, the entire share capital of Himinonic Detergents Industries Pvt. Ltd. (Him ionic) and from Kalindi Investments Pvt. Ltd., the entire share capital of Surac Holdings Pvt. Ltd. (Surac).  There upon Wadi Holdings Pvt.Ltd., the respective subsidiaries of Himionic and Surac, became subsidiaries of the company.

The acquisition of the undertakings from Elscope became effective from 1st July.

1978:

  • The acquisition of the undertakings from Ofisade became effective from May 16, but in terms of the sale agreement. the company issued further 11% Non-Convertible bonds of the face value of Rs.166 lakh to the holding companies of Sarabhai Enterprises and their subsidiaries to convert demand liabilities of that amount into deferred credits.

1981:

  • The company proposed to undertake various other schemes of expansion, diversification, modernisation, research and development including those of SG Chemicals & Pharmaceuticals. All these schemes were to be implemented during the period.
  • Standard Pharmaceuticals Ltd was amalgamated with the company with effect from April 1. Due to this amalgamation, the company derived the advantage of the industrial licences for the bulk manufacture of penicillin, Erythomycin, Ampicillin, Vitamin C, Doxy,doxycycline insulin and other pharmaceutical preparations.

1982:

It was proposed to amalgamate with the company Swastik Household& Industrial Products P. Ltd, Ambernath (Maharashtra), SM Chemicals & Electronics P Ltd. Kandivli, Bombay and WhitcoLtd, with effect from July 1.

1983:

The Scheme of Amalgamation of Swastik Household Industrial Products Pvt. Ltd. (SHIP, Pvt. Ltd) and S.M. Chemicals & Electronics Pvt. Ltd. (SMCEPL) with the company was sanctioned by the Bombay High Court and approval from the Gujarat High Courtwas received on May 12, 1987.

1984:

The company issued 15% secured non-convertible debentures for Rs 10 crore.  The issue was substantially over-subscribe and after obtaining consent to retain the excess upto 50% of the issue debentures of Rs.15 crores were allotted on February 1, 1985.

1985:

In a bid to gain access to the latest innovations in various fields of technological specialisation achieved by world leaders in the field of bulk drugs and pharmaceuticals, electronics and synthetic detergents, a scheme of reorganisation of Ambalal Sarabhai Enterprises (ASE) Ltd was evolved. Under this scheme it was proposed to divide with effect from July 1, the existing operations of ASE between ASE and its two subsidiaries to be named Sarabhai Electronics Ltd, and Sarabhai Surfactants,Ltd and give their shares to the existing shareholders of ASE.

1986:

The Scheme of Amalgamation for the merger of ASE, of its subsidiaries Himionic holdings Ltd, Wadi Holdings, Ltd, Surac Holdings, Ltd, Perion Holdings Ltd, Wadi Financiers and Investments Ltd, and Shahibag Investments Ltd with effect from July 1, was sanctioned by the High Courts of Gujarat and Bombay.

1987:

The Gujarat High Court gave its sanction for the Scheme of Amalgamation on December 24.

  • SG Chemicals & Pharmaceuticals Ltd. (SG), formerly known as Suhrid Geigy, Ltd, was a company in which Ciba-Geigy Ltd.Basle, Switzerland and its associates held 47 1/2% of the paid up capital. Ciba-Geigy discotinued its technical collaboration with SG with effect from Junuary 1, 1976.
  • As per the scheme of arrangement Sarabhai Electronics Ltd.(SEL) in which the electronics division of ASE had been vested, issued 35,82,536 of its equity shares to the shareholders of the company.
  • 1,67,400 equity shares were allotted without payment in cash to members of SHIP Pvt. Ltd and SMCPL on their merger.

1988:

The company entered into an understanding with US-based Bristol-Myers Squibb Corporation for technical know-how in the manufacture of pharmaceuticals and penicillin.  This was done with a view to takeover as a going concern the existing undertaking of Synbiotics Ltd for the manufacture of bulk drugs because the company had suffered a severe setback due to non-availability of working funds resulting in under utilisation of capacity.

  • The company disinvested in entire shareholding of 500 equity shares of Rs1000 each of its wholly owned subsidiary SG Chemicals and Dyes Trading Ltd for a consideration of Rs 200 lakh.

1989:

The company entered into technical collabortion agreements with Avesta (Sweden) and Pannevis (the Netherlands) for the manufacture of special process equipments and screen making equipment.

1996:

The company obtained industrial licences for the manufacture of: (i) fatty acids from minor edible oils, (ii) Sorbitol, and (iii) increcal (cycocel technical) an agrochemical.  Letters of Intent were in hand for the manufacture of (i) chlorine and Its salts and (ii) screen making equipment. Industrial licence for the manufacture of (i) electronic measuring and testing  instrument, (ii) closed cirucuit television systems and (iii sSpecial process equipment including vacuum dryers, sterilisers, evaporators, crystallisers, heat exchangers, etc. were in the process of being endorsed in the name of the company.  The company's application for the manufacture of computer peripheralsand micro-processors was pending with the government.

2007:

Ambalal Sarabhai Enterprises Ltd appointed B S Bohra as additional director of the company with effect from April 20, 2007.

The Group operates in two segments: pharmaceuticals and electronics.segements. It further has two divisions - Systronics Division - Systronics Division has been contributing and delivering some of the import substitute products like Double Beam UV - Visible Spectrophotometers, Photo flourimeters, etc. Further, to make the complete range available under one roof, Systronics division has entered in to strategic tie-up with some of the local and foreign manufacturers with co-branding or marketing their products like Gas Chromatographs, HPLC, Atomic Absorption spectrophotometers, FTIR, Amino Acid Analyser.

Telerad Division - The company also has Telerad division, which is one of the oldest representatives of Sony in India promoting broadcast and professional video/audio products for more than three decades. This division has expanded its services through eight  branch offices in different locations of India. Telerad division has also extended its services in the area of design, system supply, installation, integration, training, maintenance and supply of spares. The company exports its products to regions such as Japan, Europe, USA, Africa, and Middle East. Some of its subsidiaries include Synbiotics Ltd., Haryana Containers Ltd., Asence Inc. USA, and Mautik Exim Ltd.

Products Offered:

The company has following products offering

1) Therapeutic, bulk drugs and veterinary segments.

2) ASE`s formulations in the therapeutic segment include anti-infective, analgesic, anti-inflammatory, nutritional, oncological, cardiovascular, gastrointestinal, and anti diabetic products to name a few.

3) The company`s products in the bulk drug segment include Acenocoumarol, Amphotericine, Ascorbic Acid, Canrenone and Carbamazeine among others. ASE, in the animal health care market, offers a wide range of therapeutic and nutritional formulations for livestock, poultry and pets.


Subsidiaries of the Company:

  • Vovantis Lab Pvt Ltd
  • Systronics  (India) Ltd
  • Synbiotics limited
  • Suvik Hitek Pvt Ltd
  • Mautik Exim Limited
  • Haryana Containers Limited
  • Asence  Pharma Pvt.Ltd
  • Asence Inc.USA

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.91%
1 Week
+0.81%
1 Month
-11.05%
3 Month
+15.89%
6 Month
+53.85%
1 Year
+68.48%
2 Year
+165.41%
5 Year
+291.41%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -25.55 -66.09 -256.13 328.25 -57.92 4.20 7.01 40.95
Return on Capital Employed (%) 0.02 -12.98 -17.91 10.08 107.14 -11.94 16.34 13.17 27.36
Return on Assets (%) -4.62 -8.29 -9.58 -3.51 25.83 -10.30 0.62 0.99 7.84

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 36 18 -2 -9 39 25 27 31 45
Non Curr. Liab. 16 17 59 15 13 6 11 9 5
Curr. Liab. 171 175 155 163 153 124 155 171 133
Minority Int. 0 0
Equity & Liab. 223 210 211 169 204 155 193 211 183
Non Curr. Assets 123 106 144 100 92 82 80 95 79
Curr. Assets 100 105 67 68 112 73 114 116 104
Misc. Exp. not W/O
Total Assets 223 210 211 169 204 155 193 211 183

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 89 100 105 125 132 134 125 152 134
Other Income 4 16 3 13 95 6 25 5 24
Total Income 93 117 108 137 227 140 150 157 158
Total Expenditure -101 -111 -113 -129 -145 -145 -137 -146 -135
PBIDT -8 6 -6 9 82 -5 13 11 22
Interest -10 -9 -11 -10 -4 -5 -3 -3 -4
Depreciation -3 -14 -3 -5 -17 -4 -2 -2 -3
Taxation -1 -1 -1 -1 -14 -5 -7 -4 -1
Exceptional Items 11
PAT -11 -18 -20 -7 48 -19 1 2 15

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -13 -3 11 -8 -75 5 -7 19 -7
Cash Fr. Inv. 11 0 -1 10 80 -3 18 -9 17
Cash Fr. Finan. 1 3 -8 -1 -3 -6 -2 -6 -14
Net Change -1 -1 2 1 2 -4 8 3 -4
Cash & Cash Eqvt 7 6 8 8 10 5 14 17 13

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 30.76 30.76 30.76 30.76 30.76 30.76 30.76 30.76 30.76
Public 69.24 69.24 69.24 69.24 69.24 69.24 69.24 69.24 69.24
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 26 Jul 2021
Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayAMBALAL SARABHAI ENTERPRISES LTD.
2CINL52100GJ1978PLC003159
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY 0
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES



Name of the Company Secretary: Mr. Damodar H. Sejpal
Designation: Company Secretary & Compliance Officer
EmailId: dsejpal@ase.life
Name of the Chief Financial Officer: Mr. Navinchandra Patel
Designation: Chief Financial Officer
EmailId: npatel@ase.life

Date: 26/07/2021

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Thu, 08 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021 (Revised)
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- DAMODAR HARGOVINDBHAI SEJPAL
Designation :- Company Secretary and Compliance Officer
Thu, 08 Jul 2021
Shareholding for the Period Ended June 30 2021
Ambalal Sarabhai Enterprises Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 30 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%